HighTower Advisors
TAK icon

HighTower Advisors’s Takeda Pharmaceutical TAK Stock Holding History

HighTower Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10
Closed -$1K – 3669
2021
Q4 		$1K Buy
+10
New +$140 ﹤0.01% 3268

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HighTower Advisors's TAK Position: Q1 2026 in Review

HighTower Advisors increased its Takeda Pharmaceutical (TAK) stake by 8.7% in Q1 2026, buying an estimated $145K and bringing the position to 103,082 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #1740.

HighTower Advisors first reported a position in TAK in Q1 2019 and has held it in 29 quarters since. 358 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • HighTower Advisors held 103,082 shares of Takeda Pharmaceutical worth $1.91M as of Q1 2026.
  • HighTower Advisors bought 8,254 Takeda Pharmaceutical shares in Q1 2026, an estimated $145K.
  • Takeda Pharmaceutical made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #1740 holding.
  • HighTower Advisors first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 29 quarters since.
  • 358 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.